Efficacy and tolerability of minocycline for depression: A systematic review and meta-analysis of clinical trials.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of Affective Disorders

• Publication date

  2018-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jad.2017.10.042PMID 29102836
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anti-inflammatory treatments for mood disorders: Systematic review and meta-analysis

  2017cited by this paper
• Minocycline as an adjunct for treatment-resistant depressive symptoms: A pilot randomised placebo-controlled trial

  2017cited by this paper
• Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia

  2017cited by this paper
• Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial

  2017cited by this paper
• A pilot, open‐label, 8‐week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression

  2017cited by this paper
• Therapeutic effects of minocycline on mild-to-moderate depression in HIV patients: a double-blind, placebo-controlled, randomized trial

  2016cited by this paper
• Anti‐inflammatory agents in the treatment of bipolar depression: a systematic review and meta‐analysis

  2016cited by this paper
• Bipolar Disorder and Inflammation.

  2016cited by this paper
• Inflammation as a Predictive Biomarker for Response to Omega-3 Fatty Acids in Major Depressive Disorder: A Proof of Concept Study

  2015cited by this paper
• Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials.

  2014cited by this paper
• Inflamed moods: a review of the interactions between inflammation and mood disorders.

  2014cited by this paper
• A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers.

  2013cited by this paper
• Novel therapeutic targets in depression: minocycline as a candidate treatment.

  2012cited by this paper
• Minocycline as adjunctive therapy for patients with unipolar psychotic depression: an open-label study.

  2012cited by this paper
• Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression.

  2009cited by this paper
• What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression.

  2009cited by this paper
• Measuring inconsistency in meta-analyses

  2003cited by this paper
• Meta-analysis: Principles and procedures

  1997cited by this paper
• Possible antidepressant effect of minocycline.

  1996cited by this paper

• Research Progress on the Biological Function and Homeostatic Disruption of Microglia in the Pathogenesis of Major Depressive Disorder.

  2026cites this paper
• Preclinical rodent studies support minocycline as an adjunctive anxiolytic.

  2026cites this paper
• Activation of Hippocampal ACE2 Prevents the Dysbiosis-induced Depression-like Behavior in Mice by Enhanced Neurogenesis and Neuroprotection via Mas Receptor

  2025cites this paper
• Inflammatory markers and suicidal behavior: A comprehensive review of emerging evidence

  2025cites this paper
• Advancing precision psychiatry and targeted treatments: Insights from immunopsychiatry.

  2025cites this paper
• Drug screening for ischemic stroke using larvae and adult zebrafish model: a review

  2025cites this paper
• Screening of antidepressant effective active components of Pueraria and investigation of the mechanism

  2025cites this paper
• Transcriptomic activation of immune cell trafficking predicts antidepressant response to minocycline.

  2025cites this paper
• Is The Renin-Angiotensin System A Friend or Foe in Neurological Diseases? Unveiling Its Role and Therapeutic Potential.

  2025cites this paper
• Cytokine Blockade Attenuates Inflammation and Improves Depressive Psychopathology After COVID-19: A Naturalistic Observational Study

  2025cites this paper
• Commonalities and differences in gene expression patterns in major depressive disorder and chronic spontaneous urticaria: implications for comorbidity

  2025cites this paper
• Polarization to M1-type microglia in the hippocampus is involved in depression-like behavior in a mouse model of olfactory dysfunction.

  2024cites this paper
• Monoclonal antibody precision therapy targeting inflammation for bipolar disorder: a narrative review

  2024cites this paper
• Depression and the Aberrant Intestinal Microbiome.

  2024cites this paper
• Use of gene regulatory network analysis to repurpose drugs to treat bipolar disorder.

  2024cites this paper
• Efficacy of Minocycline in Depression: A Systematic Review and Meta-analysis

  2024cites this paper
• Revolutionising Neurological Therapeutics: Investigating Drug Repurposing Strategies.

  2024cites this paper
• Glycolytic metabolism: Food for immune cells, fuel for depression?

  2024cites this paper
• Effects of social dominance and acute social stress on morphology of microglia and structural integrity of the medial prefrontal cortex.

  2024cites this paper
• "Inflamed" depression: A review of the interactions between depression and inflammation and current anti-inflammatory strategies for depression.

  2024cites this paper
• New and emerging treatments for major depressive disorder

  2024cites this paper
• Minocycline Abrogates Individual Differences in Nerve Injury-Evoked Affective Disturbances in Male Rats and Prevents Associated Supraspinal Neuroinflammation

  2024cites this paper
• Antibiotic exposure and depression incidence: A cohort study of the Korean population.

  2024cites this paper
• Oxidatively-induced DNA base damage and base excision repair abnormalities in siblings of individuals with bipolar disorder DNA damage and repair in bipolar disorder

  2024cites this paper
• Inflammatory factors predicted the resilient phenotype in social defeat-induced depression of male mouse.

  2023cites this paper
• Die Bedeutung von Antidepressiva bei COVID-19 und Long-COVID – Ein Scoping-Review Update

  2023cites this paper
• Major depressive disorder

  2023cites this paper
• Minocycline in depression not responding to first-line therapy: A systematic review and meta-analysis

  2023cites this paper
• Is immune activation simply a non-specific marker of depression severity or chronicity or does it indicate an underlying pathophysiological path to depressive or other mood disorders?

  2023cites this paper
• Stressed to the Core: Inflammation and Intestinal Permeability Link Stress-Related Gut Microbiota Shifts to Mental Health Outcomes.

  2023cites this paper
• Major depressive disorder as a neuro-immune disorder: origin, mechanisms, and therapeutic opportunities.

  2023cites this paper
• Roles of microglia in adult hippocampal neurogenesis in depression and their therapeutics

  2023cites this paper
• Selective breeding of rats for high (HAB) and low (LAB) anxiety-related behaviour: A unique model for comorbid depression and social dysfunctions.

  2023cites this paper
• Efficacy and tolerability of minocycline in depressive patients with or without treatment-resistant: a meta-analysis of randomized controlled trials

  2023cites this paper
• Modulation of Gut Microbiome in Ecstasy/MDMA-Induced Behavioral and Biochemical Impairment in Rats and Potential of Post-Treatment with Anacyclus pyrethrum L. Aqueous Extract to Mitigate Adverse Effects

  2023cites this paper
• Pediatric Acute-Onset Neuropsychiatric Syndrome: Current Perspectives

  2023cites this paper
• Potential strategies to optimize the efficacy of antidepressants: Beyond the monoamine theory

  2023cites this paper
• Celecoxib for Mood Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2023cites this paper
• The interaction between kynurenine pathway, suicidal ideation and augmentation therapy with minocycline in patients with treatment-resistant depression

  2023influential citation
• Increased Inflammation and Treatment of Depression: From Resistance to Reuse, Repurposing, and Redesign.

  2023cites this paper
• Turmeronols (A and B) from Curcuma longa have anti-inflammatory effects in lipopolysaccharide-stimulated BV-2 microglial cells by reducing NF-κB signaling

  2023cites this paper
• Anti-Inflammatory Treatment Efficacy in Major Depressive Disorder: A Systematic Review of Meta-Analyses

  2023cites this paper
• Acetylsalicylic Acid and Mood Disorders: A Systematic Review

  2022cites this paper
• Matrix Metalloproteinase-9 as an Important Contributor to the Pathophysiology of Depression

  2022cites this paper
• Adjunctive minocycline for major depressive disorder: A sub-study exploring peripheral immune-inflammatory markers and associated treatment response

  2022cites this paper
• Sex differences in a double-blind randomized clinical trial with minocycline in treatment-resistant depressed patients: CRP and IL-6 as sex-specific predictors of treatment response

  2022cites this paper
• Outer membrane protein Amuc_1100 of Akkermansia muciniphila alleviates antibiotic-induced anxiety and depression-like behavior in mice.

  2022cites this paper
• Minocycline, a classic antibiotic, exerts psychotropic effects by normalizing microglial neuroinflammation-evoked tryptophan-kynurenine pathway dysregulation in chronically stressed male mice.

  2022cites this paper
• Current Perspectives on Pharmacological and Non-Pharmacological Interventions for the Inflammatory Mechanism of Unipolar Depression

  2022cites this paper
• Gut microbiota in anxiety and depression: Pathogenesis and therapeutics

  2022cites this paper
• Possible Use of Minocycline in Adjunction to Intranasal Esketamine for the Management of Difficult to Treat Depression following Extensive Pharmacogenomic Testing: Two Case Reports

  2022cites this paper
• Study protocol for a phase II, double-blind, randomised controlled trial of cannabidiol (CBD) compared with placebo for reduction of brain neuroinflammation in adults with chronic low back pain

  2022cites this paper
• Recent Advances in Psychopharmacology

  2022cites this paper
• The tetrapartite synapse in neuropsychiatric disorders: Matrix metalloproteases (MMPs) as promising targets for treatment and rational drug design.

  2022cites this paper
• Hidden agenda of Enterococcus faecalis lifestyle transition: planktonic to sessile state.

  2022cites this paper
• Obesity and the Brain

  2022cites this paper
• Is minocycline effective for treating depression?

  2022cites this paper
• Medicinal Plants and Their Impact on the Gut Microbiome in Mental Health: A Systematic Review

  2022cites this paper
• EFFECT OF MINOCYCLINE AND MINOSCYCLINE+METFORMIN ON DIABETES-RELATED DEPRESSION

  2022cites this paper
• DNA damage and repair mechanisms in bipolar disorder

  2022cites this paper
• Recent advances in the psychopharmacology of major depressive disorder

  2022cites this paper
• Antidepressant psychopharmacology: is inflammation a future target?

  2022cites this paper
• Inflammation as a Pathophysiologic Pathway to Anhedonia: Mechanisms and Therapeutic Implications.

  2022cites this paper
• Pharmacological depletion of microglia leads to a dose-dependent reduction in inflammation and senescence in the aged murine brain.

  2022cites this paper
• Inflammation and depression: Research designs to better understand the mechanistic relationships between depression, inflammation, cognitive dysfunction, and their shared risk factors

  2021cites this paper
• Novel therapeutic drug targets for bipolar disorder

  2021cites this paper
• Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial

  2021cites this paper
• Metabolic Stress and Immunity: Nutrient-Sensing Kinases and Tryptophan Metabolism.

  2021cites this paper
• Microglia activation and adult neurogenesis in the hippocampus: new clues about the antidepressant effect of minocycline.

  2021cites this paper
• Tetracyclines, a promise for neuropsychiatric disorders: from adjunctive therapy to the discovery of new targets for rational drug design in psychiatry

  2021cites this paper
• Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.

  2021cites this paper
• Selecting antidepressants according to a drug-by-environment interaction: a comparison of fluoxetine and minocycline effects in mice living either in enriched or stressful conditions.

  2021cites this paper
• Inflammation increases the development of depression behaviors in male rats after spinal cord injury

  2021cites this paper
• Differences in microglia morphological profiles reflect divergent emotional temperaments: insights from a selective breeding model

  2021cites this paper
• Microglia and HPA axis in depression: An overview of participation and relationship

  2021influential citation
• Beyond the lesion site: minocycline augments inflammation and anxiety-like behavior following SCI in rats through action on the gut microbiota

  2021cites this paper
• Neuroinflammation and the Kynurenine Pathway in CNS Disease: Molecular Mechanisms and Therapeutic Implications

  2021cites this paper
• Early-life inflammation promotes depressive symptoms in adolescence via microglial engulfment of dendritic spines.

  2021cites this paper
• Key considerations in the pharmacological management of treatment-resistant depression

  2021cites this paper
• Aiding and Abetting Anhedonia: Impact of Inflammation on the Brain and Pharmacological Implications

  2021cites this paper
• No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial.

  2021cites this paper
• Microglia and BDNF at the crossroads of stressor related disorders: Towards a unique trophic phenotype.

  2021cites this paper
• Minocycline in Major Depressive Disorder: And overview with considerations on treatment-resistance and comparisons with other psychiatric disorders

  2021cites this paper
• The future of immunopsychiatry: Three milestones to clinical innovation

  2021cites this paper
• Microglia and their LAG3 checkpoint underlie the antidepressant and neurogenesis-enhancing effects of electroconvulsive stimulation

  2021cites this paper
• New frontiers in suicide vulnerability: immune system and sex hormones

  2021cites this paper
• Curcuma longa extract improves serum inflammatory markers and mental health in healthy participants who are overweight: a randomized, double-blind, placebo-controlled trial

  2021cites this paper
• Exploring interleukin-6, lipopolysaccharide binding protein and brain-derived neurotrophic factor following 12 weeks of adjunctive minocycline treatment for depression.

  2021cites this paper
• Impact of aging and senescence on phenotype and function of murine brain microglia in vitro and in vivo Dissertation

  2021cites this paper
• Sick for science: experimental endotoxemia as a translational tool to develop and test new therapies for inflammation-associated depression

  2020cites this paper
• Depression following traumatic brain injury: a comprehensive overview

  2020cites this paper
• Managing Editor

  2020cites this paper
• Minocycline Protects Against the Degeneration of Retinal Neurons in Mice

  2020cites this paper
• Brain-immune crosstalk in the treatment of major depressive disorder.

  2020cites this paper
• Bipolar disorders.

  2020cites this paper
• Minocycline in neurodegenerative and psychiatric diseases: An update

  2020cites this paper
• The anti-inflammatory role of SSRI and SNRI in the treatment of depression: a review of human and rodent research studies

  2020cites this paper
• Minocycline alleviates depression-like symptoms by rescuing decrease in neurogenesis in dorsal hippocampus via blocking microglia activation/phagocytosis.

  2020cites this paper
• Minocycline Protects Against the Degeneration of Retinal Neurons in Mice

  2020cites this paper
• Reseach progress in neuroinflammation mechanism in depression.

  2020cites this paper